OBR – News, Perspective, Catalyst

Today's Oncology News

Opt In Search Archives

Bayer Presents Latest Data and New Research to Advance ...

(Bayer) May 11, 2021 - Updated long-term efficacy and safety data of Vitrakvi® (larotrectinib) for patients with TRK fusion cancer from an in...

Roche To Present Data From One Of The Most Comprehensiv...

(Roche) May 11, 2021 - Data from the first positive phase III study of a cancer immunotherapy in early, resected lung cancer. Studies in perso...

A Break from Chemo: PARP Inhibitor Shrinks Tumors in Pa...

(Penn Medicine) May 10, 2021 - More than two-thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing or ...

Featured Content

What is the role of ipi/nivo based treatment in advanced non-small cell lung cancer?

Mary J. Fidler, MD, elaborates on what early clinical trials have told us about sotorasib

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Toni Choueiri, MD, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, discuss clinical progress in renal cell carcinoma (RCC)

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Melissa Johnson, MD, Program Director, Lung Cancer Research, Sarah Cannon Research Institute, discuss clinical progress in Small Cell Lung Cancer (SCLC)

Maintaining oncology practice efficiency is critical in providing optimal care for patients, and leads to a better quality of life for them. At the recent COA conference, oncology stakeholders offered real-life examples and discussed ways to improve patients' overall experience at all stages of cancer, while increasing efficiency and avoiding staff burnou...

Oncology stakeholders discussed their experiences with prescribing biosimilars at the COA annual meeting, noting cost savings but also noting challenges. Shifting payer preferences for preferred therapies resulting in overcrowded pharmacies, and a lack of data and real-world evidence on long-term outcomes and safety were only some of them.

COVID-19 has highlighted health care disparities in the US, leading to poorer survival and outcomes, and gaps in cancer care for racial and ethnic minorities, and the socioeconomically-disadvantaged. COA panelists pinpointed other contributing factors to the inequities, including lack of diversity in both the oncology workforce and clinical trials populat...

Podcasts

Small Cell Lung Cancer (SCLC) – Robert Figlin, MD, and Melissa Johnson, MD, discuss clinical progress in small cell lung cancer (SCLC)

00:00

Listen on
Apple Podcasts

Listen on
Google Play

Listen on
Spotify

Title

Released

Bladder Cancer – Robert Figlin, MD, and Arjun Balar, MD, discuss clinical progress in bladder cancer

02/28/21

Prostate Cancer - Robert Figlin, MD, and Neeraj Agarwal, MD, discuss clinical progress in prostate cancer

02/22/21

Renal Cell Carcinoma (RCC) - Robert Figlin, MD and Toni Choueiri, MD, discuss clinical progress in renal cell carcino...

02/22/21

Breast Cancer – Robert Figlin, MD, and Adam Brufsky, MD, PhD, discuss clinical highlights from SABCS 2020

01/12/21

Expert Video Insights

Search by

Elisabeth Heath, MD, FACP, offers perspective on the KEYNOTE-365 clinical study

Sumanta K. Pal, MD, regarding the quality of life outcomes from CheckMate 9ER

OBR Green

View Archives

April 2021 Edition

Maintaining oncology practice efficiency is critical in providing optimal care for patients, and leads to a better quality of life for them. At the recent COA conference, oncology stakeho...

April 2021 Edition

Oncology stakeholders discussed their experiences with prescribing biosimilars at the COA annual meeting, noting cost savings but also noting challenges. Shifting payer preferences for p...

April 2021 Edition

COVID-19 has highlighted health care disparities in the US, leading to poorer survival and outcomes, and gaps in cancer care for racial and ethnic minorities, and the socioeconomically-di...

Blog

FDA Panel Endorses Four of Six Accelerated Approvals fo...

May 05, 2021

By Aaron Tallent The Food and Drug Administration (FDA) panel responsible for evaluating the safety and efficacy of oncology therapies has made recommendations...

AACR 2021: Practice-Changing Trials Show Improved Survi...

May 04, 2021

By Chase Doyle A pair of phase 3 clinical trials presented during the AACR virtual annual meeting 2021 could be practice-changing for patients with relapsed/in...

New Treatment Directions Unveiled at WCLC 2020

Feb 01, 2021

By Ted Bosworth In early stage non-small cell lung cancer (NSCLC), one source of good news at the 2020 World Conference on Lung Cancer (WCLC 2020) was the effi...

OBR Tools

Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontelligence^TM and a customized email alert system summarizing the most recent oncology-specific information available.

Learn More

The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.

Learn More